{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-098225","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.212171+00:00","generated_at":"2026-05-31T05:59:46.484711+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Theriva Biologics issues 27,316 common shares upon conversion of Series C and D preferred stock","bullets":["4,138 Series C shares converted into 1,086 common shares at $30.50 per share.","100,000 Series D shares converted into 26,230 common shares at $30.50 per share.","Total 27,316 common shares issued; no Series C or D preferred shares remain outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-098225","json":"https://secwatch.observer/filing/0001104659-24-098225.json","markdown":"https://secwatch.observer/filing/0001104659-24-098225.md","text":"https://secwatch.observer/filing/0001104659-24-098225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924098225/0001104659-24-098225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924098225/tm2423567d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:59:46.484711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}